Market Research Logo

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Summary

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive designed for schizophrenia; reCALL using virtual reality exposure therapy to treat combat posttraumatic stress disorder (PTSD); reVIVE against general anxiety disorder; and PEAR-005 to PEAR-011 for treating pain, major depressive disorder, insomnia, Parkinson's disease and inflammatory conditions. Pear Therapeutics reSET, is an FDA-authorized prescription therapeutic for substance use disorder (SUD) used as an outpatient treatment. The company works in partnership with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc., Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Pear Therapeutics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Pear Therapeutics Inc Company Overview
Pear Therapeutics Inc Company Snapshot
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
Pear Therapeutics Inc – Pipeline Analysis Overview
Pear Therapeutics Inc - Key Facts
Pear Therapeutics Inc - Major Products and Services
Pear Therapeutics Inc Pipeline Products by Development Stage
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
Pear Therapeutics Inc Pipeline Products Overview
Digital Therapeutic - Autism Spectrum Disorder
Digital Therapeutic - Autism Spectrum Disorder Product Overview
Digital Therapeutic - Cardiovascular Disease
Digital Therapeutic - Cardiovascular Disease Product Overview
Digital Therapeutic - Cognition
Digital Therapeutic - Cognition Product Overview
Digital Therapeutic - Epilepsy
Digital Therapeutic - Epilepsy Product Overview
Digital Therapeutic - Gastrointestinal Disease
Digital Therapeutic - Gastrointestinal Disease Product Overview
Digital Therapeutic - Inflammatory conditions
Digital Therapeutic - Inflammatory conditions Product Overview
Digital Therapeutic - Major Depressive Disorder
Digital Therapeutic - Major Depressive Disorder Product Overview
Digital Therapeutic - Movement Disorders
Digital Therapeutic - Movement Disorders Product Overview
Digital Therapeutic - Oncology
Digital Therapeutic - Oncology Product Overview
Digital Therapeutic - Respiratory
Digital Therapeutic - Respiratory Product Overview
PEAR-006 - Multiple Sclerosis
PEAR-006 - Multiple Sclerosis Product Overview
PEAR-006 - Multiple Sclerosis Clinical Trial
reCALL
reCALL Product Overview
reVIVE
reVIVE Product Overview
Somryst
Somryst Product Overview
Thrive
Thrive Product Overview
Thrive Clinical Trial
Pear Therapeutics Inc - Key Competitors
Pear Therapeutics Inc - Key Employees
Pear Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Pear Therapeutics Inc, Recent Developments
May 18, 2019: Pear Therapeutics to present data on reSET, for the treatment of substance use disorder, and Pear-004, for the treatment of Schizophrenia, at American Psychiatric Association Annual Meeting
May 03, 2019: Pear Therapeutics initiates feasibility study to treat depressive symptoms in people with multiple sclerosis
Jan 07, 2019: Sandoz and Pear Therapeutics announce US launch of reSET-O to help treat opioid use disorder
Dec 17, 2018: Pear Therapeutics announces initiation of proof of concept study for prescription digital therapeutic in development for the treatment of Schizophrenia
Dec 11, 2018: Sandoz and Pear Therapeutics get FDA clearance for reSET-O app
Dec 05, 2018: Pear Therapeutics presents new data on reSET and reSET-O at American Academy of Addiction Psychiatry Annual Meeting and Scientific Symposium
Nov 20, 2018: Sandoz and Pear Therapeutics launch reSET for SUD patients
Jan 16, 2018: Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder
Dec 12, 2017: Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET Prescription Digital Therapeutic
Oct 18, 2017: Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-O Prescription Digital Therapeutic to Treat Opioid Use Disorder
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
Pear Therapeutics Inc Pipeline Products by Equipment Type
Pear Therapeutics Inc Pipeline Products by Indication
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
Pear Therapeutics Inc, Key Facts
Pear Therapeutics Inc, Major Products and Services
Pear Therapeutics Inc Number of Pipeline Products by Development Stage
Pear Therapeutics Inc Pipeline Products Summary by Development Stage
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
Pear Therapeutics Inc Ongoing Clinical Trials Summary
Digital Therapeutic - Autism Spectrum Disorder - Product Status
Digital Therapeutic - Autism Spectrum Disorder - Product Description
Digital Therapeutic - Cardiovascular Disease - Product Status
Digital Therapeutic - Cardiovascular Disease - Product Description
Digital Therapeutic - Cognition - Product Status
Digital Therapeutic - Cognition - Product Description
Digital Therapeutic - Epilepsy - Product Status
Digital Therapeutic - Epilepsy - Product Description
Digital Therapeutic - Gastrointestinal Disease - Product Status
Digital Therapeutic - Gastrointestinal Disease - Product Description
Digital Therapeutic - Inflammatory conditions - Product Status
Digital Therapeutic - Inflammatory conditions - Product Description
Digital Therapeutic - Major Depressive Disorder - Product Status
Digital Therapeutic - Major Depressive Disorder - Product Description
Digital Therapeutic - Movement Disorders - Product Status
Digital Therapeutic - Movement Disorders - Product Description
Digital Therapeutic - Oncology - Product Status
Digital Therapeutic - Oncology - Product Description
Digital Therapeutic - Respiratory - Product Status
Digital Therapeutic - Respiratory - Product Description
PEAR-006 - Multiple Sclerosis - Product Status
PEAR-006 - Multiple Sclerosis - Product Description
PEAR-006 - Multiple Sclerosis - Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis
reCALL - Product Status
reCALL - Product Description
reVIVE - Product Status
reVIVE - Product Description
Somryst - Product Status
Somryst - Product Description
Thrive - Product Status
Thrive - Product Description
Thrive - A Randomized, Sham-controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia
Pear Therapeutics Inc, Key Employees
Pear Therapeutics Inc, Other Locations
Glossary
List of Figures
Pear Therapeutics Inc Pipeline Products by Equipment Type
Pear Therapeutics Inc Pipeline Products by Development Stage
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook